Clinical Trial Update: E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating E7050 plus cetuximab versus cetuximab alone in platinum-resistant squamous cell carcinoma of the head and neck has completed with pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Platinum-resistant Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Cetuximab (cetuximab)
• E7050

Snippet

Sponsor: Eisai Inc. | Conditions: Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-01-03